About Actipulse Neuroscience
Actipulse Neuroscience is a Healthcare company based in Cambridge (United States) founded in 2017 by Adrien Chatillon and Gabriel Villafuerte. Non-invasive brain stimulation technology is developed for neurodegenerative disorders. Actipulse Neuroscience has raised $125 thousand across 3 funding rounds from investors including Y Combinator, MassChallenge and Start-Up Chile. Its chief executive, as recorded, is Adrien Chatillon. Its focus areas include Life Sciences, Neurology, Medical Devices and Therapeutic Devices. Its legal entity is Actipulse Neuroscience, Inc. Its competitors include NovaVision, EnClear Therapies and AccuMedical; 3 of its 3 listed competitors have raised funding.
Company details
Actipulse Neuroscience was founded in 2017 in Cambridge, United States, within the biotechnology sector. Non-invasive devices utilizing high-frequency magnetic pulses for transcranial neuromodulation are developed to address pathogenic mechanisms in neurodegenerative disorders. Combination therapies involving drugs and neuromodulation technology are also pursued. Operations focus on research and development of these medical technologies.
- Headquarters Cambridge, United States
- Founders Adrien Chatillon, Gabriel Villafuerte
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website actipulseneuroscience.com
- Social LinkedIn
- Legal Name Actipulse Neuroscience, Inc.
- Annual Revenue$173.96 K (USD)6568as on Dec 31, 2022
- Net Profit$9.31 K (USD)138as on Dec 31, 2022
- Total Equity Funding$125K (USD)
in 3 rounds
- Latest Funding Round$125K (USD), Seed
Jan 2022
- InvestorsY Combinator
& 2 more
Funding Insights of Actipulse Neuroscience
Actipulse Neuroscience has successfully raised a total of $125K across 3 strategic funding rounds. The most recent funding activity was a Seed round of $125 thousand completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $125,000
- Total Rounds 3
- Last Round Seed — $125,000
- First Round $40,000
(May 2018)
- Investors Count 3
All 3 funding rounds of Actipulse Neuroscience with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2022 | $125,000 | Seed | – | Y Combinator | – |
| Oct 2019 | Grant | – | – | ||
| May 2018 | $40,000 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in Actipulse Neuroscience
Actipulse Neuroscience has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Y Combinator, MassChallenge and Start-Up Chile.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage startups are accelerated via funding and educational programs. | ycombinator.com | Mountain View, United States | ||
Early-stage entrepreneurs are accelerated through MassChallenge's program. | masschallenge.org | Boston, United States | ||
Government-backed startup accelerator programs are operated in Chile. | startupchile.org | Santiago, Chile |
Investor details for Actipulse Neuroscience
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Actipulse Neuroscience
8 people are tracked at Actipulse Neuroscience (4 in leadership, 4 in team).
| Name | Role | Group |
|---|---|---|
Adrien Chatillon | Co-Founder & CEO | Leadership |
Gabriel Villafuerte | Co-Founder & CMO | Leadership |
Rubén Francisco Sosa Oliveros | Head Of Engineering Department | Leadership |
Gabriel Villafuerte MD, PhD | Chief Medical Officer | Leadership |
Emilio Bazán Sánchez | Software Engineer | Team |
Miguel Armas | Research Hardware Engineer | Team |
Ernesto Villafuerte Jiménez | Almacenista Y Compras | Team |
Esteban Galicia Romero | Manager Of Health Regulation, Quality And Internal Control In Medical Devices | Team |
Complete people profiles for Actipulse Neuroscience
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Actipulse Neuroscience
3 dated milestones of Actipulse Neuroscience across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Actipulse Neuroscience is founded.
- Funding First funding round of $40K.
- Funding Latest funding round, Seed, of $125K.
Competitors of Actipulse Neuroscience
Actipulse Neuroscience has 3 listed competitors in our database, 3 of them funded. They include NovaVision, EnClear Therapies and AccuMedical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| novavision.com | 2003 | Boca Raton, United States | $38M | Non-invasive devices are developed for vision restoration in stroke survivors. | ||
| encleartherapies.com | 2018 | Cambridge, United States | $12.72M | Developer of device-based therapies to treat neurodegenerative disorders | ||
| accumedical.cn | 2016 | Santa Ana, United States | $14.28M | Neurovascular interventional devices for neurological disorders are developed. |
Detailed competitors of Actipulse Neuroscience
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Actipulse Neuroscience (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Actipulse Neuroscience
Complete news archive for Actipulse Neuroscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Actipulse Neuroscience
Actipulse Neuroscience was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Actipulse Neuroscience is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Adrien Chatillon is the CEO of Actipulse Neuroscience, as recorded in our data. They have also founded this company.
Actipulse Neuroscience is a funded company, having raised a total of $125K across 3 funding rounds to date. The company's 1st funding round was a Grant of $40K, raised on May 2018.
Annual revenue of Actipulse Neuroscience is $173.96K as on Dec 31, 2022.
Actipulse Neuroscience was founded in 2017 in Cambridge, United States, within the biotechnology sector. Non-invasive devices utilizing high-frequency magnetic pulses for transcranial neuromodulation are developed to address pathogenic mechanisms in neurodegenerative disorders. Combination therapies involving drugs and neuromodulation technology are also pursued. Operations focus on research and development of these medical technologies.
Actipulse Neuroscience's top competitors include NovaVision, EnClear Therapies and AccuMedical.
Actipulse Neuroscience has 3 investors. Key investors include Y Combinator, MassChallenge, and Start-Up Chile.
Actipulse Neuroscience operates through Actipulse Neuroscience, Inc..